



NRG-GU015 The ARCHER Trial: A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

[Click here to Listen](#)

Episode Description: Our co-hosts welcome Dr. Scott Delacroix and Dr. Himanshu Nagar to discuss bladder cancer, bladder preservation, and the newly activated NRG-GU015 (ARCHER) clinical trial. In this episode, the experts explore who may benefit from bladder-sparing chemoradiation, dispel common misconceptions about organ preservation, and explain how GU015 is evaluating a shorter, adaptive radiation treatment approach that could make curative therapy more accessible for patients with muscle-invasive bladder cancer. T



All episodes of The NRG Oncology Podcast can be found on Spotify, Apple Music, YouTube, & Amazon or you can stream them directly from our website at

www.NRGOnco.org/Podcast